Showing 1711-1720 of 2320 results for "".
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a
- Galderma Launches Twyneo in the UShttps://practicaldermatology.com/news/galderma-launches-twyneo-in-the-us/2461128/Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the American Academy of Dermatology (AAD) Annual Meeting. Twyneo Cream features patented microencapsulation technology t
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff.
- New AAD, Industry Collab to Increase Number of Black, Latino, and Indigenous Physicians in Dermatologyhttps://practicaldermatology.com/news/new-aad-industry-collab-to-increase-number-of-black-latino-and-indigenous-physicians-in-dermatology/2461120/The American Academy of Dermatology (AAD) in collaboration with Johnson & Johnson Consumer Health and the Janssen Pharmaceutical Companies of Johnson & Johnson is launching “Pathways: Inclusivity in Dermatology” to increase the number of practicing dermatologists in the U.S. w
- Study: Use of DermTech’s Melanoma Test Can Cut Costshttps://practicaldermatology.com/news/study-use-of-dermtechs-melanoma-test-can-cut-costs/2461102/New research shows that DermTech’s Pigmented Lesion Assay can reduce costs for commercial health insurance plans when it’s incorporated into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma The
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The